NCT Number: NCT04631744
Phase: Phase 2
Trial Summary: The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym:
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives